Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results